Clin2
NCT06971848Possibly a fitRecruiting

Skin testing for biologic drug allergies

Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckMelanoma NeoplasmsSmall Cell Bronchial CarcinomasBronchial CarcinomaPleural MesotheliomaHodgkin's LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma

Part of Blood & lymphatic, Cancer, Digestive system, Heart & circulation, Hormones & metabolism, Immune system & allergy, Lungs & breathing clinical trials.

This trial checks if people can safely receive certain biologic drugs without allergic reactions, using skin tests to see how the body reacts. It may help find out if you are allergic to a biologic medicine you have taken before.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
70 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You were treated with one of the study drugs (like Atezolizumab, Nivolumab, or Pembrolizumab) and have had at least two doses without any allergic reaction.
  • You have health insurance or are covered by medical care assurance.
  • You have given written permission to join the study.
  • If you take steroids or allergy pills, you need to stop them for at least one week before the skin tests (using inhaled steroids is okay).
  • You do not have any skin rashes or conditions like psoriasis or eczema that could affect the test results.
  • You are not pregnant, breastfeeding, in detention, or under legal protection.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07327489Recruiting
Live tumor biopsy study to predict immunotherapy response

This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.

Fort Smith, Arkansas
NCT04045470Recruiting
Skin-device test to find drugs for T-cell lymphoma lesions

This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.

Boston, Massachusetts
NCT07376512Not yet recruiting
Blood test to predict immunotherapy response in lung cancer and melanoma

This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.

Besançon
NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment

This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.

Paris
NCT05649683Recruiting
Blood immune testing to predict melanoma response to immunotherapy

This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.

Nice, Alpes-maritimes
NCT07192315Not yet recruiting
Predicting immunotherapy reactions and safety in cancer patients

This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.

Marseille

Hear when a new Pleural Mesothelioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.